Molecular Partners (VTX:MOLN) Full Year 2022 Results
Key Financial Results
Revenue: CHF189.6m (up by CHF179.8m from FY 2021).
Net income: CHF117.9m (up from CHF63.8m loss in FY 2021).
Profit margin: 62% (up from net loss in FY 2021). The move to profitability was primarily driven by higher revenue.
EPS: CHF3.63 (up from CHF2.06 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Molecular Partners Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.0%.
Looking ahead, revenue is expected to decline by 19% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%.
The company's shares are down 3.0% from a week ago.
We should say that we've discovered 2 warning signs for Molecular Partners (1 shouldn't be ignored!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here